Latest DURECT Corporation Stories
CUPERTINO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that the previously announced development and license agreement with Alpharma Ireland Limited, an affiliate of Alpharma Inc. , granting such party the exclusive worldwide rights to develop and commercialize ELADUR(TM), DURECT's investigational transdermal bupivacaine patch, has cleared review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and has become effective. (Logo:...
Apharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, announced today that its affiliate has entered into a license agreement with DURECT Corporation (NASDAQ: DRRX) of Cupertino, California for the exclusive worldwide rights to develop and commercialize an investigational transdermal bupivacaine patch currently under development for the treatment of pain associated with post-herpetic neuralgia ("PHN"). "Today's announcement continues to solidify Alpharma's position as a...
CUPERTINO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- DURECT Corporation today reported that Pain Therapeutics , its licensee, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid pain drug candidate based on DURECT's patented ORADUR(TM) technology. This is the third ORADUR-based opioid drug candidate covered by DURECT's collaboration with Pain Therapeutics, for which King Pharmaceuticals holds the...
CUPERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY(R) and granted Priority Review. The FDA typically grants Priority Review to drug candidates that have the potential to demonstrate significant improvements compared to marketed products. The FDA goal for completing review of a drug with Priority Review status is six months from the date the application...
CUPERTINO, Calif., June 30 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that the US Food and Drug Administration (FDA) has granted to DURECT orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia (PHN). Bupivacaine is the active pharmaceutical ingredient in ELADUR(TM), DURECT's investigational transdermal drug patch. If ELADUR is the first bupivacaine product approved for PHN, under the 1983 Orphan Drug Act ELADUR will...
